

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Project: Health Care for the Homeless Program User/Visit Surveys—New

The Bureau of Primary Health Care (BPHC) of HRSA is planning to conduct User/Visit Surveys of the Health Care for Homeless Program (HCHP). The

purpose of this study is to conduct nationally representative surveys, which have the following components: (1) A personal interview survey of HCHP site users; and (2) a record-based study of visits to HCHP sites.

The HCHP is the Federal program with the sole responsibility for addressing the critical primary health care needs of homeless individuals. The HCHP is administered by the BPHC. The BPHC is interested in knowing more about the general and specific characteristics of the HCHP users and their visits to the HCHP sites. As a consequence, a personal interview survey (User Survey) will be administered to a nationally representative sample of HCHP users and a representative sample of medical visits of HCHP sites (Visit Survey) will be examined as well. These surveys are designed and intended to be primary sources of information on the health and

visits of the HCHP users. The information will provide policymakers with a better understanding of the services that HCHP users are receiving at HCHP sites and how well these sites are meeting the needs of HCHP users.

Data from the surveys will provide quantitative information on the homeless population served by the HCHP, specifically: (a) Sociodemographic characteristics, (b) health care access and utilization, (c) health status and morbidity, (d) health care experiences and risk behaviors, (e) content of medical encounters, (f) preventive care, and (g) living conditions. These surveys will provide data useful to the HCHP and will enable HRSA to provide data required by Congress under the Government Performance and Results Act of 1993.

The estimated burden on respondents and HCHP site staff is as follows:

Form	Number of respondents	Hours per respondent	Total hour burden
Users of HCHP Sites	1000	1	1000
Abstraction of Visit Records by HCHP Site Staff	1000	.25	250
Total	1000	1,250

Send comments to Susan Queen, Ph.D., HRSA Reports Clearance Officer, Room 11-05, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: March 4, 2002.

Jane M. Harrison,

Director, Division of Policy Review and Coordination.

[FR Doc. 02-5488 Filed 3-6-02; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Advisory Committee; Notice of Meetings; Addendum

In **Federal Register** Document 01-28108, appearing on pages 56689-56690 in the issue for Friday, November 9, 2001, the following meetings for the Health Professions and Nurse Education Special Emphasis Panel have been added:

Name: Allied Health Projects.
Date and Time: April 8-11, 2002.
Place: Holiday Inn Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.
Open on: April 8, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: April 8, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); April 9-11, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Quentin N. Burdick Program for Rural Interdisciplinary Training.

Date and Time: April 8-11-2002.
Place: Holiday Inn Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.
Open on: April 8, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: April 8, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); April 9-11, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Residency Training in Primary Care.
Date and Time: April 22-25, 2002.
Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.

Open on: April 22, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: April 22, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); April 23-25, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Physician Assistant Training in Primary Care.
Date and Time: April 22-25, 2002.
Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.
Open on: April 22, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: April 22, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); April 23-25, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Faculty Development Training in Primary Care.

Date and Time: April 29-May 2, 2002.
Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.
Open on: April 29, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: April 29, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); April 30-May 2, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Geriatric Education Centers.
Date and Time: April 29-May 2, 2002.
Place: Holiday Inn Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.
Open on: April 29, 8:00 a.m. to 10:00 a.m.
Closed on: April 29, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); April 30-May 2, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Residency Training in Primary Care.
Date and Time: May 6-9, 2002.
Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.
Open on: May 6, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: May 6, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); May 7-9, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Residencies in the Practice of Pediatric Dentistry and Residencies and Advanced Education in the Practice of General Dentistry.
Date and Time: May 6-9, 2002.
Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.
Open on: May 6, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: May 6, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); May

7–9, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Predoctoral Training in Primary Care.

Date and Time: May 13–16, 2002.

Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.

Open on: May 13, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: May 13, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); May 14–16, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Geriatric Training for Physicians, Dentists, and Behavioral and Mental Health Professionals.

Date and Time: May 13–16, 2002.

Place: Holiday Inn Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

Open on: May 13, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: May 13, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); May 14–16, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Academic Administrative Units in Primary Care.

Date and Time: May 20–23, 2002.

Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.

Open on: May 20, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: May 20, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); May 21–23, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Geriatric Academic Career Awards.

Date and Time: June 3–6, 2002.

Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.

Open on: June 3, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: June 3, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); June 4–6, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Health Education and Training Centers.

Date and Time: June 10–13, 2002.

Place: Holiday Inn Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

Open on: June 10, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: June 10, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); June 11–13, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: Graduate Psychology Education Program.

Date and Time: July 29–August 1, 2002.

Place: Holiday Inn Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910.

Open on: July 29, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: July 29, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); July 30–August 1, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Name: National Research Service Awards.

Date and Time: August 5–6, 2002.

Place: Hilton Silver Spring, 8727 Colesville Road, Silver Spring, MD 20910.

Open on: August 5, 2002, 8:00 a.m. to 10:00 a.m.

Closed on: August 5, 2002, 10:00 a.m. to adjournment (approximately 6:00 p.m.); August 6, 2002, 8:00 a.m. to adjournment (approximately 6:00 p.m.).

Dated: March 1, 2002.

Jane M. Harrison,

Director, Division of Policy Review and Coordination.

[FR Doc. 02–5357 Filed 3–6–02; 8:45 am]

BILLING CODE 4165–15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Opportunity for a Cooperative Research and Development Agreement (CRADA) To Develop Live Attenuated Dengue Viruses for Use as Vaccines in Humans

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) is seeking Capability Statements from parties interested in entering into a Cooperative Research and Development Agreement (CRADA) on a project to develop live attenuated dengue viruses for use as vaccines to prevent dengue hemorrhagic fever and dengue shock syndrome in humans. This project is part of ongoing vaccine development activities in the Laboratory of Infectious Diseases (LID), Division of Intramural Research, NIAID.

DATES: Only written CRADA Capability Statements received by the NIAID on or before April 18, 2002, will be considered.

ADDRESSES: Capability Statements should be submitted to Dr. Michael R. Mowatt, Office of Technology Development, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 31 Center Drive MSC 2137, Building 31, Room 3B62, Bethesda, MD 20892–2137; Tel: 301/496–2644, Fax: 301/402–7123; Electronic mail: mmowatt@nih.gov.

SUPPLEMENTARY INFORMATION: The CRADA will employ attenuated dengue virus strains (types 1 through 4) developed in LID using recombinant DNA methodologies to (1) identify and characterize the mutations responsible for attenuation, (2) engineer viral strains suitably attenuated for use as human vaccines, and (3) evaluate the attenuated viruses as live vaccines in animals, including rhesus monkeys, and humans. The Public Health Service (PHS) has filed patent applications both in the

U.S. and internationally related to these technologies.

The LID has extensive experience in evaluating the safety, immunogenicity and efficacy of various human viral pathogens and vaccines thereof both in experimental animals and human volunteers. The LID has identified two approaches to produce attenuated dengue virus vaccine candidates each incorporating a stable, clinically tested deletion mutation capable of attenuating dengue viruses for humans. In addition, a large set of additional attenuating mutations have been identified that will be available to further attenuate vaccine candidates that prove to be incompletely attenuated in human trials. The Collaborator in this endeavor is expected to commit several scientists off-site to support the activities defined by the CRADA Research Plan. These scientists, in collaboration with investigators in the LID, would coordinate the production and release testing of the candidate vaccines, generate monoclonal antibodies or other antibodies needed for production and characterization of clinical lots, and use molecular virologic techniques to generate attenuating mutations suitable for use in live vaccine candidates. The LID and Collaborator will identify the best candidate dengue virus attenuated derivatives for each of the four dengue virus serotypes to formulate a tetravalent vaccine. In addition, it is expected that the Collaborator will provide funds to supplement LID's research budget for the project and would make a major funding commitment to support the safety, immunogenicity and efficacy studies for candidate vaccines developed under the CRADA.

The capability statement must address, with specificity and providing appropriate examples, each of the following selection criteria: (1) The technical expertise of the Collaborator's Principal Investigator and laboratory group in molecular virology; (2) The number of personnel that the Collaborator plans to assign to this project; (3) Ability of Collaborator to manufacture experimental vaccine lots for parenteral administration under Good Manufacturing Practices (GMP) conditions and the number of lots that could be produced annually, (4) Access to a qualified bank of cells for vaccine manufacture, specifically Vero cells or DBS FRhL–2 cells, (5) Capability to manage regulatory affairs attendant to licensure by FDA and international regulatory bodies, and (6) Ability to provide adequate and sustained funding to support pre-clinical development at NIH and at collaborator's site and for the